Cerevance Media Center
Current News
April 25, 2024
Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline
Cerevance announced an initial closing of its Series B-1 Extension financing round that will add $47 million to the $51 million previously raised bringing the total Series B-1 raise to $98 million.
April 22, 2024
Cerevance Publishes CVN293 in ACS Medicinal Chemistry Letters
Cerevance announces that the peer-reviewed journal, ACS Medicinal Chemistry Letters, has published the manuscript titled “Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment”.
February 15, 2024
Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters
Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters describing the discovery and initial development of CVN766 in the peer-reviewed journal, Bioorganic & Medicinal Chemistry Letters. In the publication titled, “Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist”
November 13, 2023
Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease
Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease
News Archive
April 17, 2024
Cerevance Presents at 35th Symposium on Medicinal Chemistry in Eastern England
Cerevance announces plans to deliver an oral presentation at the upcoming 35th Symposium on Medicinal Chemistry, taking place in Hatfield, United Kingdom April 25, 2024.
By leveraging Cerevance’s exclusive Nuclear Enriched Transcript Sort Sequencing (NETSseq) platform, KCNK13 emerged as an ion channel demonstrating remarkably precise expression in microglia, with upregulation observed across multiple disease conditions. CVN293, Cerevance’s molecule undergoing a Phase 1 clinical study, was designed to specifically target KCNK13. Its potential as an anti-inflammatory therapy in individuals afflicted with Alzheimer’s disease and Amyotrophic lateral sclerosis, wherein it acts as a blocker, will be reviewed.
April 2, 2024
Cerevance to Participate at the 23rd Annual Needham Virtual Health Care Conference
March 13, 2024
Cerevance Announces Presentation at Alzheimer’s Research UK Conference
February 27, 2024
Cerevance Announces Presentation at AD/PD™ 2024 International Conference
Events Archive
April 8, 2024
Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment
March 15, 2024
Differential contribution of THIK‑1 K+ channels and P2X7 receptors to ATP‑mediated neuroinflammation by human microglia
March 7, 2024
NETSseq reveals deep molecular insights into astrocyte biology and identifies novel therapeutic targets for Alzheimer’s disease
February 12, 2024
Discovery and First-time Disclosure of CVN766, an Exquisitely Selective Orexin 1 Receptor Antagonist
December 25, 2023
NETSseq Advances the Understanding of Neuronal Vulnerability in AD Progression Facilitating the Identification of Novel Therapeutic Targets at the Single Cell Type Level
November 15, 2023